National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years--United States, 2013

Laurie D Elam-Evans, David Yankey, Jenny Jeyarajah, James A Singleton, Robinette C Curtis, Jessica MacNeil, Susan Hariri, Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Laurie D Elam-Evans, David Yankey, Jenny Jeyarajah, James A Singleton, Robinette C Curtis, Jessica MacNeil, Susan Hariri, Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC)

Abstract

The Advisory Committee on Immunization Practices (ACIP) recommends that adolescents routinely receive 1 dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine, 2 doses of meningococcal conjugate (MenACWY) vaccine, and 3 doses of human papillomavirus (HPV) vaccine.* ACIP also recommends administration of "catch-up"† vaccinations, such as measles, mumps, and rubella (MMR), hepatitis B, and varicella, and, for all persons aged ≥6 months, an annual influenza vaccination. ACIP recommends administration of all age-appropriate vaccines during a single visit. To assess vaccination coverage among adolescents aged 13-17 years, CDC analyzed data from the 2013 National Immunization Survey-Teen (NIS-Teen).§ This report summarizes the results of that analysis, which show that from 2012 to 2013, coverage increased for each of the vaccines routinely recommended for adolescents: from 84.6% to 86.0% for ≥1 Tdap dose; from 74.0% to 77.8% for ≥1 MenACWY dose; from 53.8% to 57.3% for ≥1 HPV dose among females, and from 20.8% to 34.6% for ≥1 HPV dose among males. Coverage varied by state and local jurisdictions and by U.S. Department of Health and Human Services (HHS) region. Healthy People 2020 vaccination targets for adolescents aged 13-15 years were reached in 42 states for ≥1 Tdap dose, 18 for ≥1 MenACWY dose, and 11 for ≥2 varicella doses. No state met the target for ≥3 HPV doses.¶ Use of patient reminder and recall systems, immunization information systems, coverage assessment and feedback to clinicians, clinician reminders, standing orders, and other interventions can help make use of every health care visit to ensure that adolescents are fully protected from vaccine-preventable infections and cancers (5), especially when such interventions are coupled with clinicians' vaccination recommendations.

Figures

FIGURE
FIGURE
Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17 years, by survey year — National Immunization Survey-Teen, United States, 2006–2013 Abbreviations: Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis; MenACWY = meningococcal conjugate; HPV = human papillomavirus. * ≥1 dose Tdap vaccine on or after age 10 years. † ≥1 dose MenACWY vaccine. § HPV vaccine, either bivalent or quadrivalent, among females. The Advisory Committee on Immunization Practices (ACIP) recommends either bivalent or quadrivalent vaccine for females. ¶ HPV vaccine, either bivalent or quadrivalent, among males. ACIP recommends the quadrivalent vaccine for males; however, some males might have received bivalent vaccine.

References

    1. Akinsanya-Beysolow I Advisory Committee on Immunization Practices (ACIP), ACIP Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years—United States, 2014. MMWR. 2014;63:108–9.
    1. CDC. Recommendations on the use of quadrivalent human papillomavirus vaccine in males—Advisory Committee on Immunization Practices (ACIP), 2011. MMWR. 2011;60:1705–8.
    1. CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR. 2011;60(RR-2)
    1. US Department of Health and Human Services. Healthy People 2020. Washington, DC: US Department of Health and Human Services; 2012. Available at .
    1. Community Preventive Services Task Force. Increasing appropriate vaccination. Atlanta, GA: Community Preventive Services Task Force; 2014. Available at .
    1. CDC. Updated recommendations for use of meningococcal conjugate vaccines—Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. 2011;60:72–6.
    1. CDC. National and state vaccination coverage among adolescents aged 13–17 years—United States, 2012. MMWR. 2013;62:685–93.
    1. Holmon DM, Bernard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to human papillomavirus vaccination among U.S. adolescents: a systematic review of the literature. JAMA Pediatr. 2014;168:76–82.
    1. Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014—United States. MMWR. 2014;63:620–4.
    1. CDC. National, state, and local area vaccination coverage among children aged 19–35 months—United States, 2012. MMWR. 2013;62:733–40.

Source: PubMed

3
Abonner